The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Bogolepova A.N.

Rossiĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Moskva

Chukanova E.I.

Rossiĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Moskva

Smirnova M.Iu.

Chukanova A.S.

Gracheva I.Iu.

Semushkina E.G.

The use of valdoxan in the treatment of post-stroke depression

Authors:

Bogolepova A.N., Chukanova E.I., Smirnova M.Iu., Chukanova A.S., Gracheva I.Iu., Semushkina E.G.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(4): 42‑46

Read: 1655 times

Download PDF (RU)
Contact the author
Table of contents

THE USE OF VALDOXAN IN THE TREATMENT OF POST-STROKE DEPRESSION
THE USE OF VALDOXAN IN THE TREATMENT OF POST-STROKE DEPRESSION

To cite this article:

Bogolepova AN, Chukanova EI, Smirnova MIu, Chukanova AS, Gracheva IIu, Semushkina EG. The use of valdoxan in the treatment of post-stroke depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(4):42‑46. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Sequential use of botu­linum toxin A and bovhyaluronidase azoximer in the correction of post-stroke spasticity. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):80-85
Cognitive vascular diso­rders and morphometric para­meters of the prefrontal, dorsolateral cortex and thalamus in post-stroke patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):91-95
Central nervous system invo­lvement in systemic lupus erythematosus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):124-129
Effe­ctiveness of comprehensive reha­bilitation of patients after a stroke in terms of changes in clinical and functional characteristics. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):11-16
Nutrition correction in the complex therapy and reha­bilitation of the posttraumatic stress diso­rder. Russian Journal of Preventive Medi­cine. 2025;(2):114-119
Digi­tal dental approach in reha­bilitation of a patient treated for unilateral anky­losis of a temporomandibular joint using condylotomy. Stomatology. 2025;(1):9-16
Hand burns in pediatrics. Piro­gov Russian Journal of Surgery. 2025;(3):96-106
Possibilities of vibroacoustic therapy application in patients with chro­nic bronchopulmonary pathology. Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(1):12-18
Reha­bilitation of patients with post-COVID syndrome depe­nding on C(159)T poly­morphism of SD-14 gene. Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(1):42-50
Effe­ctiveness of muscles’ preoperative preparation for reco­nstruction of ante­rior cruciate liga­ment of knee. Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(1):51-57
Abstract:

Forty patients, aged from 55 to 85 years, with post-stroke depression received valdoxan in dosage of 25 mg daily during 3 months. Patient's state was assessed with a battery of scales (The Hamilton depression scale, MMSE, Tinnetti scale etc). The high antidepressive effect and good tolerability of the drug were demonstrated. The improvement of movement and cognitive functions, together with the stabilization of the emotional state, was seen.

Keywords:

ischemic stroke
post-stroke depression
rehabilitation
valdoxan (agomelatin).

Authors:

Bogolepova A.N.

Rossiĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Moskva

Chukanova E.I.

Rossiĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Moskva

Smirnova M.Iu.

Chukanova A.S.

Gracheva I.Iu.

Semushkina E.G.

Close metadata

References:

  1. Volel' B.A. Val'doksan (agomelatin): innovatsionnyi mekhanizm deistviya. Psikhiatriya i psikhofarmakoterapiya 2008; 3: 35-39.
  2. Gusev E.I., Gekht A.B., Bogolepova A.N., Sorokina I.B. Osobennosti depressivnogo sindroma u bol'nykh, perenesshikh ishemicheskii insul't. Zhurn nevrol i psikhiat. Prilozhenie "Insul't" 2001; 3: 28-31.
  3. Gusev E.I., Bogolepova A.N. Depressivnye rasstroistva u bol'nykh, perenesshikh insul't. Zhurn nevrol i psikhiat. Prilozhenie "Insul't" 2008; 22: 10-16.
  4. Ivanov S.V. Val'doksan (agomelatin) pri terapii umerennykh i tyazhelykh depressii nepsikhoticheskogo urovnya v ambulatornoi i gospital'noi praktike (rezul'taty Rossiiskogo mul'titsentrovogo issledovaniya "KhRONOS"). Psikhiatriya i psikhofarmakoterapiya 2009; 6: 14-17.
  5. Kompleks meropriyatii po profilaktike, diagnostike i lecheniyu bol'nykh, stradayushchikh serdechno-sosudistymi zabolevaniyami, v Rossiiskoi Federatsii. Federal'naya programma. Materialy II Rossiiskogo mezhdunarodnogo kongressa "Tserebrovaskulyarnaya patologiya i insul't" 2007; 7: 20.
  6. Medvedev V.E. Perspektivy ispol'zovaniya melatoninergicheskikh preparatov v terapii depressii u patsientov s serdechno-sosudistymi zabolevaniyami. Psikhiatriya i psikhofarmakoterapiya 2010; 3: 17-22.
  7. Medvedev V.E., Epifanov A.V. Innovatsionnyi metod terapii depressii u patsientov s ishemicheskoi bolezn'yu serdtsa. Obozrenie psikhiatrii i meditsinskoi psikhologii im. Bekhtereva 2010; 3, 31-36.
  8. Skvortsova V.I. Snizhenie zabolevaemosti, smertnosti i invalidnosti ot insul'tov v Rossiiskoi Federatsii. Zhurn nevrol i psikhiat. Prilozhenie "Insul't" (spetsvypusk, materialy II Rossiiskogo mezhdunarodnogo kongressa "Tserebrovaskulyarnaya patologiya i insul't") 2007; 25-27.
  9. Smulevich A.B., Ivanov S.V. Depressiya i biologicheskie ritmy: anketnoe issledovanie TsIRKADIAN-I. Psikhiatriya i psikhofarmakoterapiya 2008; 6: 4-8.
  10. Syromyatnikova L.I., Spigina T.A., Shestakov V.V. Tsirkadiannyi ritm i depressiya u kardiologicheskikh patsientov. Psikhicheskie rasstroistva v obshchei meditsine 2010; 1: 19-24.
  11. Berg A., Palomäki H., Lehtihalmes M. et al. Poststroke depression an 18-month follow-up. Stroke 2003; 34: 138-143.
  12. Berg A., Lonnqvist J., Palomaki H., Kaste M. Assessment of depression after stroke. A comparison of different screening instruments. Stroke 2009; 40: 523-529.
  13. Bourin M., Mocaër E., Porsolt R. Antidepressant-like activity of S20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci 2004; 29: 2: 126-133.
  14. Eser D., Baghai Th.C., Möller H.-J. Agomelatine: The evidence for its place in the treatment of depression. Core Evidence 2009; 3: 171-179.
  15. Goodwin G.M., Rouillon F., Emsley R. Long-term treatment with agomelatine: prevention of relapse in patients with major depressive disorder over 10 months [abstract]. In: 21st European College of Neuropsychopharmacology Congress; 30 Aug-3 Sept 2008; Barselone. Spain. Eur Neuropsychopharma-col 2008; 18: 338-339.
  16. Haacke C., Althaus A., Spottke A. et al. Long-term outcome after stroke evaluating Health-Related Quality of Life using utility measurements. Stroke 2006; 37: 193-198.
  17. Joliat M.J., Schmidt M.E., Fava M. et al. Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine. J Clin Psychiatry 2004; 65: 373-378.
  18. Jonas B.S., Lando J.F. Negative affect as a prospective risk factor for hypertension. Psychosom Med 2000; 62: 188-196.
  19. Lader M. Pharmacotherapy of mood disorders and treatment discontinuation. Drugs 2007; 67: 1657-63.
  20. Lindén Th., Blomstrand Ch., Skoog I. Depressive Disorders After 20 Months in Elderly Stroke Patients: A Case-Control Study. Stroke 2007; 38: 1860-1863.
  21. Lo R.S.K., Cheng J.O.Y., Wong E.M.C. et al. Handicap and its determinants of change in stroke survivors one-year follow-up study. Stroke 2008; 39: 148-153.
  22. Loo H., Hale A., D'haenen H. Opredelenie dozy Val'doksana, melatoninergicheskogo agonista i selektivnogo 5-HT2s-antagonista, v terapii bol'shogo depressivnogo rasstroistva: dvoinoe slepoe kontroliruemoe platsebo issledovanie s ranzhirovaniem doz (referat). Psikhiatriya i psikhofarmakoterapiya 2009; 2: 52-58.
  23. Mendelson S.D. The current status of the platelet 5-HT receptor in depression. J Affect Disord 2002; 57: 13-24.
  24. Millan M.J., Gobert A., Lejeune F. et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydro-xytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306: 954-964.
  25. Montgomery S.A., Kennedy S.H., Burrows G.D. et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19: 271-280.
  26. Montgomery S.A., Oli J.-P., Keennedy S.H. Antidepressants efficacy of agomelatine in major depressive disorder: meta-analysis of three pivotal studies. Eur Neuropsychopharmacol 2006; 16: Suppl 4: 321.
  27. Murray V., Von Arbin M., Bartfai A. et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. J Clin Psychiatry 2005; 66: 708-716.
  28. Musselman D.L., Betan E., Larsen H., Phillips L.S. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry 2003; 54: 317-329.
  29. Narushima K., Kosier J.T., Robinson R.G. A reappraisal of poststroke depression, intra- and inter-hemispheric lesion location using meta-analysis. The Journal of Neuropsychiatry and Clinical Neurosciences 2003; 15: 422-430.
  30. Pan J.H., Song X.Y., Lee S.Y. et al. Longitudinal analysis of quality of life for stroke survivors using latent curve models. Stroke 2008; 39: 2795-2802.
  31. Paul S.L., Dewey H.M., Sturm J.W. et al. Prevalence of depression and use of antidepressant medication at 5-years poststroke in the North East Melbourne Stroke Incidence Study. Stroke 2006; 37: 2854-2855.
  32. Quera Salva M.A., Vanier B., Laredo J. et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol 2007; 10: 691-696.
  33. Robinson R.G., Spalletta G., Jorge R.E. et al. Decreased heart rate variability is associated with poststroke Depression. Am J Geriatr Psychiatry 2008; 16: 11: 867-873.
  34. Santos M., Gold G., Kovari E. et al. Differential impact of lacunes and microvascular lesions on poststroke depression. Stroke 2009; 40: 3557-3562.
  35. Sturm J.W., Donnan G.A., Dewey H.M. et al. Determinants of handicap after stroke: the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2004; 35: 715-720.
  36. Vataja R., LeppaEvuori A., Pohjasvaara T. et al. Poststroke depression and lesion location revisited. The Journal of Neuropsychiatry and Clinical Neurosciences 2004; 16:156-162.
  37. Wassertheil-Smoller S., Applegate W.B., Berge K. et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systoloc Hypertension in the elderly). Archives of internal medicine 1996; 156: 5: 553-561.
  38. Whyte E.M., Mulsant B.H., Vanderbilt J. et al. Depression after stroke: a prospective epidemiology study. J Am Geriatr Soc 2004; 52: 774-778.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.